Aclaris Therapeutics ACRS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $8.37M-52.9% | $7.83M-58.2% | $15.74M-41.9% | $16.79M-47.6% | $17.78M-42.9% | ||
| $1.98M-20.4% | $2.09M-25.1% | $2.26M-19.5% | $2.38M-20.8% | $2.49M-27.3% | ||
| $56.72M+60.6% | $52.65M+56.7% | $45.09M-11.9% | $38.02M-45.0% | $35.33M-58.8% | ||
| $22.58M+5.0% | $21.97M-1.0% | $21.35M-16.2% | $22.13M-17.7% | $21.5M-29.4% | ||
| $428K-38.2% | $454K-43.7% | $495K-44.5% | $564K-39.5% | $692K-23.8% | ||
| $88.85M-44.1% | $84.2M-47.6% | $169.06M+130% | $163.43M+64.4% | $158.86M+35.2% | ||
| -$80.48M+43.0% | -$76.38M+46.2% | -$153.32M-231% | -$146.64M-118% | -$141.08M-63.3% | ||
| -961.9%-168pp | -975.9%-218pp | -973.9%-803pp | -873.4%-663pp | -793.6%-516pp | ||
| $6.99M-14.1% | $7.64M-4.0% | $8.11M+0.8% | $8.28M-1.0% | $8.13M— | ||
| $10.82M-0.5% | $11.45M+16.1% | $11.64M+30.3% | $11.99M+43.3% | $10.88M+24.4% | ||
| -$69.66M+46.5% | -$64.92M+50.8% | -$141.68M-283% | -$134.65M-129% | -$130.21M-68.5% | ||
| -832.6%-100pp | -829.6%-124pp | -900%-763pp | -802%-619pp | -732.4%-484pp | ||
| -$0.56+64.8% | -$0.53+69.0% | -$1.58-204% | -$1.57-91.5% | -$1.59-45.9% | ||
| -$0.56+64.8% | -$0.53+69.0% | -$1.58-204% | -$1.57-91.5% | -$1.59-45.9% | ||
| 496.6M+45.0% | 490.2M+68.4% | 444.9M+56.9% | 393.6M+39.1% | 342.4M+21.3% | ||
| 496.6M+45.0% | 490.2M+68.4% | 444.9M+56.9% | 393.6M+39.1% | 342.4M+21.3% | ||
| —— | $2.3M— | —— | —— | —— | ||
| -$70.07M+45.9% | -$64.41M+51.2% | -$141.51M-299% | -$133.71M-130% | -$129.41M-67.5% | ||
| —— | —— | —— | —— | —— | ||
| $5.58M-55.9% | $5.19M-59.0% | $12.85M+31.5% | $12.7M-17.4% | $12.65M-13.6% | ||
| -$412K— | $513K— | —— | —— | —— | ||
| -$412K— | $513K— | —— | —— | —— | ||
| $8.37M-52.9% | $7.83M-58.2% | $15.74M-41.9% | $16.79M-47.6% | $17.78M-42.9% | ||
| $3.84M— | $3.82M— | $3.53M— | $3.71M— | —— | ||
| -$80.48M+43.0% | -$76.38M+46.2% | -$153.32M-231% | -$146.64M-118% | -$141.08M-63.3% | ||
| -$80.06M+43.0% | -$75.92M+46.2% | -$152.82M-237% | -$146.07M-120% | -$140.39M-64.3% | ||
| -$80.06M+43.0% | -$75.92M+46.2% | -$152.82M-237% | -$146.07M-120% | -$140.39M-64.3% | ||
| -956.8%-167pp | -970.1%-216pp | -970.8%-803pp | -870.1%-662pp | -789.7%-515pp | ||
| -$80.48M+43.0% | -$76.38M+46.2% | -$153.32M-231% | -$146.64M-118% | -$141.08M-63.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Aclaris Therapeutics's revenue?
- Aclaris Therapeutics (ACRS) generated $8.4M in revenue over the trailing twelve months, down 52.9% year over year.
- Is Aclaris Therapeutics profitable?
- Aclaris Therapeutics is not currently profitable: it reported a net loss of $69.7M over the trailing twelve months, a -832.6% net margin.
- What are Aclaris Therapeutics's profit margins?
- Gross margin is 76.3% and operating margin is -961.9%, with a -832.6% net margin.
- What is Aclaris Therapeutics's earnings per share?
- Aclaris Therapeutics's diluted EPS over the trailing twelve months is $-0.56.
- Where does Aclaris Therapeutics's income statement data come from?
- Every line is extracted from Aclaris Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
